Enhancing cancer radiotherapy efficacy using NanOx, a novel oxygenating perfluorocarbon nanoemulsion that reverses tumour hypoxia.

Radiotherapy is used to treat over 50% of cancer patients. It is often used in combination with surgery, chemotherapy, and immunotherapy, for cancers of the breast, lung, oesophagus, and rectum. Ionising radiation predominantly exerts its anti-cancer effect through both direct DNA damage and indirectly via water radiolysis and the production of reactive oxygen species.

Profiling current cancer survivorship practices and enhancing survivorship care in public hospitals in Victoria, Australia.

Purpose: Comprehensive survivorship care involves cancer surveillance, management of post-treatment effects, health promotion and coordination between care sectors. This study aimed to understand current survivorship practices, build awareness and support improved survivorship care in Victoria, Australia.

Methods: This project had three components: (1) a survey of 20 Victorian clinical sites, assessing elements described in the Victorian Quality Cancer Survivorship Framework; (2) educational webinars for oncology health professionals, to increase survivorship knowledge and awareness; (3) implementation of targeted survivorship care quality initiatives in a sample of health services.

Relevant propositions for Y chromosome interpretation.

The Y chromosomal haplotype is expected to be identical (or close to, depending on the mutation rate) among a male and many of his paternal relatives. This means that often the same evidential value for the DNA evidence is obtained, whether the true donor or one of his close paternal relatives is compared to a crime sample. Commentators (see for example the UK Forensic Science Regulator or Amorim) have suggested to change the proposition pair to compare the probability of the evidence if the Person of Interest (POI) or one of his close paternal relatives left the DNA to the probability of the evidence if an unrelated male from the population left the DNA.

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation.

TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. Dual BTK and BCL2-inhibition with or without anti-CD20 monoclonal antibody therapy has shown promising activity in TP53-mutant MCL. We conducted a multi-center phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated MCL patients with TP53 mutation.

Human perceptions of social robot deception behaviors: an exploratory analysis.

Introduction: Robots are being introduced into increasingly social environments. As these robots become more ingrained in social spaces, they will have to abide by the social norms that guide human interactions. At times, however, robots will violate norms and perhaps even deceive their human interaction partners.